Prognostic Impact of Liver Metastases on [177Lu]Lu-PSMA Therapy Outcomes in Metastatic Castration-Resistant Prostate Cancer. (PubMed, Nucl Med Mol Imaging) - Oct 3, 2026 - "Nevertheless, approximately 50.0% of liver-metastatic patients achieved clinically meaningful PSA responses, and the treatment was well tolerated with low severe toxicity. Results indicate visceral disease primarily impacts efficacy rather than safety, supporting ongoing use of [177Lu]Lu-PSMA-617 in this population."
Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Disorders • Oncology • Prostate Cancer • Solid Tumor
|
|
Amirreza Shamshirgaran; Atena Aghaee; Emran Askari; Fatemeh Aboutalebi; Hessamoddin Roustaei; Kamran Aryana; Mohammad Hadi Samadi; Pegah Sahafi; Sara Harsini; Somaye Barashki; Susan Shafiei
|